Alpha-synuclein repeat variants and survival in parkinson's disease

Sun Ju Chung, Joanna M Biernacka, Sebastian M. Armasu, Kari Anderson, Roberta Frigerio, Jan O. Aasly, Grazia Annesi, Anna Rita Bentivoglio, Laura Brighina, Marie Christine Chartier-Harlin, Stefano Goldwurm, Georgios Hadjigeorgiou, Barbara Jasinska-Myga, Beom Seok Jeon, Yun Joong Kim, Rejko Krüger, Suzanne Lesage, Katerina Markopoulou, George Mellick, Karen E. MorrisonAndreas Puschmann, Eng King Tan, David Crosiers, Jessie Theuns, Christine Van Broeckhoven, Karin Wirdefeldt, Zbigniew K Wszolek, Alexis Elbaz, Demetrius M. Maraganore, Gilad Yahalom, Yael Orlev, Oren S. Cohen, Evgenia Kozlova, Eitan Friedman, Rivka Inzelberg, Sharon Hassin-Baer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: To determine whether α-synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods: Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow-up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results: Twenty-one sites contributed data for 6,154 cases. There was no significant association between α-synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95% confidence interval: 1.01-1.10; P value=0.01). Conclusions: In our large consortium study, α-synuclein REP1 genotypes were not associated with survival in PD. Further studies of α-synuclein's role in disease progression and long-term outcomes are needed.

Original languageEnglish (US)
Pages (from-to)1053-1057
Number of pages5
JournalMovement Disorders
Volume29
Issue number8
DOIs
StatePublished - 2014

Fingerprint

alpha-Synuclein
Synucleins
Parkinson Disease
Genotype
Dinucleotide Repeats
Molecular Epidemiology
Proportional Hazards Models
Disease Progression
Research Personnel
Confidence Intervals

Keywords

  • Association
  • Gene
  • Parkinson's disease
  • Survival
  • α-synuclein

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Chung, S. J., Biernacka, J. M., Armasu, S. M., Anderson, K., Frigerio, R., Aasly, J. O., ... Hassin-Baer, S. (2014). Alpha-synuclein repeat variants and survival in parkinson's disease. Movement Disorders, 29(8), 1053-1057. https://doi.org/10.1002/mds.25841

Alpha-synuclein repeat variants and survival in parkinson's disease. / Chung, Sun Ju; Biernacka, Joanna M; Armasu, Sebastian M.; Anderson, Kari; Frigerio, Roberta; Aasly, Jan O.; Annesi, Grazia; Bentivoglio, Anna Rita; Brighina, Laura; Chartier-Harlin, Marie Christine; Goldwurm, Stefano; Hadjigeorgiou, Georgios; Jasinska-Myga, Barbara; Jeon, Beom Seok; Kim, Yun Joong; Krüger, Rejko; Lesage, Suzanne; Markopoulou, Katerina; Mellick, George; Morrison, Karen E.; Puschmann, Andreas; Tan, Eng King; Crosiers, David; Theuns, Jessie; Van Broeckhoven, Christine; Wirdefeldt, Karin; Wszolek, Zbigniew K; Elbaz, Alexis; Maraganore, Demetrius M.; Yahalom, Gilad; Orlev, Yael; Cohen, Oren S.; Kozlova, Evgenia; Friedman, Eitan; Inzelberg, Rivka; Hassin-Baer, Sharon.

In: Movement Disorders, Vol. 29, No. 8, 2014, p. 1053-1057.

Research output: Contribution to journalArticle

Chung, SJ, Biernacka, JM, Armasu, SM, Anderson, K, Frigerio, R, Aasly, JO, Annesi, G, Bentivoglio, AR, Brighina, L, Chartier-Harlin, MC, Goldwurm, S, Hadjigeorgiou, G, Jasinska-Myga, B, Jeon, BS, Kim, YJ, Krüger, R, Lesage, S, Markopoulou, K, Mellick, G, Morrison, KE, Puschmann, A, Tan, EK, Crosiers, D, Theuns, J, Van Broeckhoven, C, Wirdefeldt, K, Wszolek, ZK, Elbaz, A, Maraganore, DM, Yahalom, G, Orlev, Y, Cohen, OS, Kozlova, E, Friedman, E, Inzelberg, R & Hassin-Baer, S 2014, 'Alpha-synuclein repeat variants and survival in parkinson's disease', Movement Disorders, vol. 29, no. 8, pp. 1053-1057. https://doi.org/10.1002/mds.25841
Chung, Sun Ju ; Biernacka, Joanna M ; Armasu, Sebastian M. ; Anderson, Kari ; Frigerio, Roberta ; Aasly, Jan O. ; Annesi, Grazia ; Bentivoglio, Anna Rita ; Brighina, Laura ; Chartier-Harlin, Marie Christine ; Goldwurm, Stefano ; Hadjigeorgiou, Georgios ; Jasinska-Myga, Barbara ; Jeon, Beom Seok ; Kim, Yun Joong ; Krüger, Rejko ; Lesage, Suzanne ; Markopoulou, Katerina ; Mellick, George ; Morrison, Karen E. ; Puschmann, Andreas ; Tan, Eng King ; Crosiers, David ; Theuns, Jessie ; Van Broeckhoven, Christine ; Wirdefeldt, Karin ; Wszolek, Zbigniew K ; Elbaz, Alexis ; Maraganore, Demetrius M. ; Yahalom, Gilad ; Orlev, Yael ; Cohen, Oren S. ; Kozlova, Evgenia ; Friedman, Eitan ; Inzelberg, Rivka ; Hassin-Baer, Sharon. / Alpha-synuclein repeat variants and survival in parkinson's disease. In: Movement Disorders. 2014 ; Vol. 29, No. 8. pp. 1053-1057.
@article{859a0e800cdc42a69d65c42840c2ffff,
title = "Alpha-synuclein repeat variants and survival in parkinson's disease",
abstract = "Objectives: To determine whether α-synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods: Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow-up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results: Twenty-one sites contributed data for 6,154 cases. There was no significant association between α-synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95{\%} confidence interval: 1.01-1.10; P value=0.01). Conclusions: In our large consortium study, α-synuclein REP1 genotypes were not associated with survival in PD. Further studies of α-synuclein's role in disease progression and long-term outcomes are needed.",
keywords = "Association, Gene, Parkinson's disease, Survival, α-synuclein",
author = "Chung, {Sun Ju} and Biernacka, {Joanna M} and Armasu, {Sebastian M.} and Kari Anderson and Roberta Frigerio and Aasly, {Jan O.} and Grazia Annesi and Bentivoglio, {Anna Rita} and Laura Brighina and Chartier-Harlin, {Marie Christine} and Stefano Goldwurm and Georgios Hadjigeorgiou and Barbara Jasinska-Myga and Jeon, {Beom Seok} and Kim, {Yun Joong} and Rejko Kr{\"u}ger and Suzanne Lesage and Katerina Markopoulou and George Mellick and Morrison, {Karen E.} and Andreas Puschmann and Tan, {Eng King} and David Crosiers and Jessie Theuns and {Van Broeckhoven}, Christine and Karin Wirdefeldt and Wszolek, {Zbigniew K} and Alexis Elbaz and Maraganore, {Demetrius M.} and Gilad Yahalom and Yael Orlev and Cohen, {Oren S.} and Evgenia Kozlova and Eitan Friedman and Rivka Inzelberg and Sharon Hassin-Baer",
year = "2014",
doi = "10.1002/mds.25841",
language = "English (US)",
volume = "29",
pages = "1053--1057",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Alpha-synuclein repeat variants and survival in parkinson's disease

AU - Chung, Sun Ju

AU - Biernacka, Joanna M

AU - Armasu, Sebastian M.

AU - Anderson, Kari

AU - Frigerio, Roberta

AU - Aasly, Jan O.

AU - Annesi, Grazia

AU - Bentivoglio, Anna Rita

AU - Brighina, Laura

AU - Chartier-Harlin, Marie Christine

AU - Goldwurm, Stefano

AU - Hadjigeorgiou, Georgios

AU - Jasinska-Myga, Barbara

AU - Jeon, Beom Seok

AU - Kim, Yun Joong

AU - Krüger, Rejko

AU - Lesage, Suzanne

AU - Markopoulou, Katerina

AU - Mellick, George

AU - Morrison, Karen E.

AU - Puschmann, Andreas

AU - Tan, Eng King

AU - Crosiers, David

AU - Theuns, Jessie

AU - Van Broeckhoven, Christine

AU - Wirdefeldt, Karin

AU - Wszolek, Zbigniew K

AU - Elbaz, Alexis

AU - Maraganore, Demetrius M.

AU - Yahalom, Gilad

AU - Orlev, Yael

AU - Cohen, Oren S.

AU - Kozlova, Evgenia

AU - Friedman, Eitan

AU - Inzelberg, Rivka

AU - Hassin-Baer, Sharon

PY - 2014

Y1 - 2014

N2 - Objectives: To determine whether α-synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods: Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow-up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results: Twenty-one sites contributed data for 6,154 cases. There was no significant association between α-synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95% confidence interval: 1.01-1.10; P value=0.01). Conclusions: In our large consortium study, α-synuclein REP1 genotypes were not associated with survival in PD. Further studies of α-synuclein's role in disease progression and long-term outcomes are needed.

AB - Objectives: To determine whether α-synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods: Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow-up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results: Twenty-one sites contributed data for 6,154 cases. There was no significant association between α-synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95% confidence interval: 1.01-1.10; P value=0.01). Conclusions: In our large consortium study, α-synuclein REP1 genotypes were not associated with survival in PD. Further studies of α-synuclein's role in disease progression and long-term outcomes are needed.

KW - Association

KW - Gene

KW - Parkinson's disease

KW - Survival

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=84904431856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904431856&partnerID=8YFLogxK

U2 - 10.1002/mds.25841

DO - 10.1002/mds.25841

M3 - Article

C2 - 24578302

AN - SCOPUS:84904431856

VL - 29

SP - 1053

EP - 1057

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -